

2020

Annett, S., Moore, G., Short, A., Marshall, A., McCrudden, C., Yakkundi, A., Das, S., McCluggage, W., Nelson, L., Harley, I., deFazio, A., Brand, A., Sharma, R., et al (2020). FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. *British Journal of Cancer*, 122(3), 361-371. [More Information]

Gorringe, K., Cheasley, D., Wakefield, M., Ryland, G., Allan, P., Alsop, K., Amarasinghe, K., Ananda, S., Bowtell, D., Christie, M., deFazio, A., et al (2020). Therapeutic options for mucinous ovarian carcinoma. *Gynecologic Oncology*, 156(3), 552-560. [More Information]

2019

Meagher, N., Wang, L., Rambau, P., Intermaggio, M., Huntsman, D., Wilkens, L., El-Bahrawy, M., Ness, R., Odunsi, K., Steed, H., Kennedy, C., Sharma, R., Harnett, P., deFazio, A., et al (2019). A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, 32(12), 1834-1846. [More Information]

Lucas, N., Robinson, A., Espersen, M., Mahboob, S., Xavier, D., Xue, J., Balleine, R., deFazio, A., Hains, P., Robinson, P. (2019). Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry. *Journal of Proteome Research*, 18(1), 399-405. [More Information]

Grant, D., Manichaikul, A., Alberg, A., Bandera, E., Barnholtz-Sloan, J., Bondy, M., Cote, M., Funkhouser, E., Moorman, P., Peres, L., deFazio, A., Kennedy, C., et al (2019). Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, 8(5), 2503-2513. [More Information]

Yang, Y., Wu, L., Shu, X., Lu, Y., Shu, X., Cai, Q., Beeghly-Fadiel, A., Li, B., Ye, F., Berchuck, A., deFazio, A., et al (2019). Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. *Cancer Research*, 79(3), 505-517. [More Information]

Saner, F., Herschtal, A., Nelson, B., deFazio, A., Goode, E., Ramus, S., Pandey, A., Beach, J., Fereday, S., Berchuck, A., et al (2019). Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews. Cancer*, 19(6), 339-348. [More Information]

Minlikeeva, A., Cannioto, R., Jensen, A., Kjaer, S., Jordan, S., Diergaard, B., Szender, J., Odunsi, K., Almohanna, H., Mayor, P., deFazio, A., et al (2019). Joint exposure to smoking, excessive weight, and physical inactivity and survival of

ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, 30(5), 537-547. [More Information]

Christie, E., Pattnaik, S., Beach, J., Copeland, A., Rashoo, N., Fereday, S., Hendley, J., Alsop, K., Brady, S., Lamb, G., deFazio, A., et al (2019). Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. *Nature Communications*, 10(1), 1-10. [More Information]

Kok, P., Beale, P., O'Connell, R., Grant, P., Bonaventura, T., Scurry, J., Antill, Y., Goh, J., Sjoquist, K., deFazio, A., Mapagu, C., et al (2019). PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. *Journal of Gynecologic Oncology*, 30(5), 1-14. [More Information]

Tang, M., O'Connell, R., Amant, F., Beale, P., McNally, O., Sjoquist, K., Grant, P., Davis, A., Sykes, P., Mileskin, L., Moujaber, T., Kennedy, C., deFazio, A., et al (2019). PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. *Gynecologic Oncology*, 154(3), 531-538. [More Information]

Jiang, X., Finucane, H., Schumacher, F., Schmit, S., Tyrer, J., Han, Y., Michailidou, K., Lesueur, C., Kuchenbaecker, K., deFazio, A., et al (2019). Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, 10(1), 1-23. [More Information]

Nagle, C., Ibiebele, T., Shivappa, N., Hebert, J., deFazio, A., Webb, P. (2019). The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer. *European Journal of Nutrition*, 58(4), 1747-1756. [More Information]

Cheasley, D., Wakefield, M., Ryland, G., Allan, P., Alsop, K., Amarasinghe, K., Ananda, S., Anglesio, M., Au-Yeung, G., Bohm, M., Brand, A., deFazio, A., Chiew, Y., Kennedy, C., Sharma, R., et al (2019). The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nature Communications*, 10(1), 1-11. [More Information]

2018

Lu, Y., Beeghly-Fadiel, A., Wu, L., Guo, X., Li, B., Schildkraut, J., Kyung Im, H., Chen, Y., Permuth, J., Reid, B., deFazio, A., et al (2018). A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. *Cancer Research*, 78(18), 5419-5430. [More Information]

Rambau, P., Vierkant, R., Intermaggio, M., Kelemen, L., Goodman, M., Herpel, E., Pharoah, P., Kommoss, S., Jimenez-

Linan, M., Karlan, B., Sharma, R., Harnett, P., Kennedy, C., deFazio, A., et al (2018). Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *The Journal of Pathology: Clinical Research*, 4(4), 250-261. [More Information]

Moujaber, T., Etemadmoghadam, D., Kennedy, C., Chiew, Y., Balleine, R., Saunders, C., Wain, G., Gao, B., Hogg, R., Srirangan, S., Harnett, P., deFazio, A., et al (2018). BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. *JCO Precision Oncology*. [More Information]

Jung, M., Russell, A., Kennedy, C., Gifford, A., Mallitt, K., Sivarajasingam, S., Bowtell, D., deFazio, A., Haber, M., Norris, M., et al (2018). Clinical importance of Myc family oncogene aberrations in epithelial ovarian cancer. *JNCI Cancer Spectrum*, 2(3), 1-9. [More Information]

Beesley, V., Smith, D., Nagle, C., Friedlander, M., Grant, P., deFazio, A., Webb, P. (2018). Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. *Supportive Care in Cancer*, 26(12), 4133-4142. [More Information]

Meagher, N., Schuster, K., Voss, A., Budden, T., Pang, C., deFazio, A., Ramus, S., Friedlander, M. (2018). Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. *Gynecologic Oncology*, 150(3), 527-533. [More Information]

Gao, B., Lu, Y., Nieuweboer, A., Xu, H., Beesley, J., Boere, I., De Graan, A., de Bruijn, P., Gurney, H., Kennedy, C., Chiew, Y., Harnett, P., Balleine, R., deFazio, A., et al (2018). Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. *Scientific Reports*, 8(1), 1-10. [More Information]

Garsed, D., Alsop, K., Fereday, S., Emmanuel, C., Kennedy, C., Etemadmoghadam, D., Gao, B., GebSKI, V., Gares, V., Christie, E., Sharma, R., Brand, A., Harnett, P., deFazio, A., et al (2018). Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. *Clinical Cancer Research*, 24(3), 569-580. [More Information]

Po, J., Roohullah, A., Lynch, D., deFazio, A., Harrison, M., Harnett, P., Kennedy, C., de Souza, P., Becker, T. (2018). Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. *Journal of Circulating Biomarkers*, 7, 1-10. [More Information]

Kondrashova, O., Topp, M., Nestic, K., Lieschke, E., Ho, G., Harrell, M., Zapparoli, G., Hadley, A., Holian, R., deFazio, A., et al (2018). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. *Nature Communications*, 9(1), 1-16. [More Information]

Block, M., Vierkant, R., Rambau, P., Winham, S., Wagner, P., Traficante, N., Toloczko, A., Tiezzi, D., Taran, F., Sharma, R., Kennedy, C., Hung, J., Harnett, P., Gao, B., deFazio, A., et al (2018). MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, 93(3), 307-320. [More Information]

Lindemann, K., Gao, B., Mapagu, C., Fereday, S., Emmanuel, C., Alsop, K., Traficante, N., Harnett, P., Bowtell, D., deFazio, A. (2018). Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. *Gynecologic Oncology*, 150(2), 239-246. [More Information]

Ring, B., Murali, R., Soslow, R., Bowtell, D., Fereday, S., deFazio, A., Traficante, N., Kennedy, C., Brand, A., Sharma, R., Harnett, P., et al (2018). Transducin-Like enhancer of split 3 (TLE3) expression is associated with taxane sensitivity in nonserous ovarian carcinoma in a three-Cohort study. *Cancer Epidemiology Biomarkers and Prevention*, 27(6), 680-688. [More Information]

2017

Jung, M., Russell, A., Liu, B., George, J., Liu, P., Liu, T., deFazio, A., Bowtell, D., Oberthuer, A., London, W., et al (2017). A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. *Cancer Research*, 77(4), 971-981. [More Information]

Glubb, D., Johnatty, S., Quinn, M., Ojuzi, Mara, T., Tyrer, J., Gao, B., Fasching, P., Beckmann, M., Lambrechts, D., Vergote, I., deFazio, A., Kennedy, C., et al (2017). Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget*, 8(39), 64670-64684. [More Information]

Praestegaard, C., Jensen, A., Jensen, S., Nielsen, T., Webb, P., Nagle, C., deFazio, A., Hogdall, E., Rossing, M., Doherty, J., et al (2017). Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, 140(11), 2422-2435. [More Information]

Henry, C., Emmanuel, C., Lambie, N., Loo, C., Kan, B., Kennedy, C., deFazio, A., Hacker, N., Ford, C. (2017). Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer. *Translational Oncology*, 10(3), 346-356. [More Information]

Goode, E., Block, M., Kalli, K., Vierkant, R., Chen, W., Fogarty, Z., Gentry-Maharaj, A., Toloczko, A., Hein, A., Gao, B., Kennedy, C., Hung, J., Harnett, P., deFazio, A., et al (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, 3(12), 1-9. [More Information]

Etemadmoghadam, D., Azar, W., Lei, Y., Moujaber, T., Garsed, D., Kennedy, C., Fereday, S., Mitchell, C., Chiew, Y., Hendley, J., Sharma, R., Harnett, P., deFazio, A., et al (2017). EIF1AX and NRAS mutations co-occur and cooperate in low-grade

serous ovarian carcinomas. *Cancer Research*, 77(16), 4268-4278. [More Information]

Minlikeeva, A., Freudenheim, J., Eng, K., Cannioto, R., Friel, G., Szender, J., Segal, B., Odunsi, K., Mayor, P., deFazio, A., et al (2017). History of comorbidities and survival of ovarian cancer patients, results from the ovarian cancer association consortium. *Cancer Epidemiology Biomarkers and Prevention*, 26(9), 1470-1473. [More Information]

Minlikeeva, A., Freudenheim, J., Cannioto, R., Szender, J., Eng, K., Modugno, F., Ness, R., LaMonte, M., Friel, G., deFazio, A., et al (2017). History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. *Cancer Causes and Control*, 28(5), 469-486. [More Information]

Minlikeeva, A., Freudenheim, J., Cannioto, R., Eng, K., Szender, J., Mayor, P., Etter, J., Cramer, D., Diergaarde, B., deFazio, A., et al (2017). History of thyroid disease and survival of ovarian cancer patients: Results from the Ovarian Cancer Association Consortium, a brief report. *British Journal of Cancer*, 117(7), 1063-1069. [More Information]

Phelan, C., Kuchenbaecker, K., Tyrer, J., Karr, S., Lawrenson, K., Winham, S., Dennis, J., Pirie, A., Riggan, M., Chornokur, G., Chiew, Y., deFazio, A., Hung, J., Kennedy, C., et al (2017). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, 49(5), 680-691. [More Information]

Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileschkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptor positive platinum-resistant or -refractory recurrent ovarian cancer. *International Journal of Gynecological Cancer*, 27(5), 900-906. [More Information]

Babic, A., Cramer, D., Kelemen, L., Kobel, M., Steed, H., Webb, P., Johnatty, S., deFazio, A., Lambrechts, D., Goodman, M., et al (2017). Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, 28(5), 459-468. [More Information]

Dixon, S., Nagle, C., Wentzensen, N., Trabert, B., Beeghly-Fadiel, A., Schildkraut, J., Moysich, K., deFazio, A., Risch, H., Rossing, M., et al (2017). Use of common analgesic medications and ovarian cancer survival: Results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, 116(9), 1223-1228. [More Information]

2016

Usset, J., Raghavan, R., Tyrer, J., McGuire, V., Sieh, W., Webb, P., Chang-Claude, J., Rudolph, A., Anton-Culver, H., deFazio, A., et al (2016). Assessment of multifactor gene-environment interactions and ovarian cancer risk: candidate genes, obesity, and hormone-related risk factors. *Cancer Epidemiology Biomarkers and Prevention*, 25(5), 780-790. [More Information]

Harrington, B., he, Y., Davies, C., Wallace, S., Adams, M., Beaven, E., Roche, D., Kennedy, C., Chetty, N., Crandon, A., deFazio, A., et al (2016). Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. *British Journal of Clinical Pharmacology*, 114(4), 417-426. [More Information]

French, J., Johnatty, S., Lu, Y., Beesley, J., Gao, B., Kalimutho, M., Henderson, M., Russell, A., Kar, S., Chen, X., Harnett, P., deFazio, A., et al (2016). Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget*, 7(6), 6353-6368. [More Information]

Price, M., Butow, P., Bell, M., deFazio, A., Friedlander, M., Fardell, J., Protani, M., Webb, P. (2016). Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making? *Supportive Care in Cancer*, 24(6), 2627-2634. [More Information]

Winham, S., Pirie, A., Chen, Y., Larson, M., Fogarty, Z., Earp, M., Anton-Culver, H., Bandera, E., Cramer, D., deFazio, A., Chenevix-Trench, G., et al (2016). Investigation of exomic variants associated with overall survival in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, 25(3), 446-454. [More Information]

Hollestelle, A., van der Baan, F., Berchuck, A., Johnatty, S., Aben, K., Agnarsson, B., Aittomaki, K., Alducci, E., Andrulis, I., Balleine, R., Carter, J., deFazio, A., et al (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, 141(2), 386-401. [More Information]

Cannioto, R., LaMonte, M., Kelemen, L., Risch, H., Eng, K., Minlikeeva, A., Hong, C., Szender, J., Sucheston-Campbell, L., Joseph, J., deFazio, A., et al (2016). Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: Evidence from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, 115(1), 95-101. [More Information]

Gao, B., Lindemann, K., Anderson, L., Fereday, S., Hung, J., Alsop, K., Tothill, R., GebSKI, V., Kennedy, C., Balleine, R., Harnett, P., deFazio, A., et al (2016). Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. *Gynecologic Oncology*, 142(3), 458-464. [More Information]

Dickson, K., Cole, A., Gill, A., Clarkson, A., Gard, G., Chou, A., Kennedy, C., Henderson, B., Fereday, S., Traficante, N., deFazio, A., Clifton-Bligh, R., Marsh, D., et al (2016). The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. *Human Molecular Genetics*, 25(24), 5460-5471. [More Information]

2015

Nagle, C., Ibiebele, T., deFazio, A., Protani, M., Webb, P.

(2015). Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. *Cancer Epidemiology*, 39(2), 196-199. [More Information]

Webb, P., deFazio, A., Protani, M., Ibiebele, T., Nagle, C., Brand, A., Blomfield, P., Grant, P., Perrin, L., Neale, R. (2015). Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. *American Journal of Clinical Nutrition*, 102(1), 109-114. [More Information]

Lawrenson, K., Li, Q., Kar, S., Seo, J., Tyrer, J., Spindler, T., Lee, J., Chen, Y., Karst, A., Drapkin, R., et al (2015). Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, 6, 1-14. [More Information]

Johnatty, S., Tyrer, J., Kar, S., Beesley, J., Lu, Y., Gao, B., Fasching, P., Hein, A., Ekici, A., Beckmann, M., Kennedy, C., Chiew, Y., deFazio, A., et al (2015). Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, 21(23), 5264-5276. [More Information]

Candido-dos-Reis, F., Song, H., Goode, E., Cunningham, J., Fridley, B., Larson, M., Alsop, K., Dicks, E., Harrington, P., Ramus, S., deFazio, A., et al (2015). Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. *Clinical Cancer Research*, 21(3), 652-657. [More Information]

Lei, Y., Henderson, B., Emmanuel, C., Harnett, P., deFazio, A. (2015). Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. *Oncogene*, 34(4), 485-495. [More Information]

Hunter, S., Anglesio, M., Ryland, G., Sharma, R., Chiew, Y., Rowley, S., Doyle, M., Li, J., Gilks, B., Moss, P., deFazio, A., et al (2015). Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. *Oncotarget*, 6(35), 37663-37677. [More Information]

Nagle, C., Dixon, S., Jensen, A., Kjaer, S., Modugno, F., deFazio, A., Feredaye, S., Hung, J., Johnatty, S., Fasching, P., et al (2015). Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, 113(5), 817-826. [More Information]

Tembe, V., Martino-Echarri, E., Marzec, K., Mok, M., Brodie, K., Mills, K., Lei, Y., deFazio, A., Rizos, H., Kettle, E., Henderson, B., et al (2015). The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. *Cellular Signalling*, 27(9), 1763-1771. [More Information]

Patch, A., Christie, E., Etemadmoghadam, D., Garsed, D., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P., Kennedy, C., Hung, J., Chiew, Y., Harnett, P.,

McNally, O., deFazio, A., et al (2015). Whole-genome characterization of chemoresistant ovarian cancer. *Nature*, 521(7553), 489-494. [More Information]

2014

Hedditch, E., Gao, B., Russell, A., Li, Y., Emmanuel, C., Beesley, J., Johnatty, S., Chen, X., Harnett, P., George, J., deFazio, A., et al (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. *Journal of the National Cancer Institute*, 106(7), 1-11. [More Information]

Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. *Gynecologic Oncology*, 132(3), 690-697. [More Information]

Dixon, S., Ibiebele, T., Protani, M., Beesley, J., deFazio, A., Crandon, A., Gard, G., Rome, R., Webb, P., Nagle, C. (2014). Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. *Gynecologic Oncology*, 132(3), 566-572. [More Information]

Kobel, M., Madore, J., Ramus, S., Clarke, B., Pharoah, P., Deen, S., Bowtell, D., Odunsi, K., Menon, U., Morrison, C., deFazio, A., et al (2014). Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *British Journal of Cancer*, 111(12), 2297-2307. [More Information]

Ghoussaini, M., Edwards, S., Michailidou, K., Nord, S., Cowper-Sal-lari, R., Desai, K., Kar, S., Hillman, K., Kaufmann, S., Glubb, D., deFazio, A., et al (2014). Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, 4, 1-12. [More Information]

Emmanuel, C., Chiew, Y., George, J., Etemadmoghadam, D., Anglesio, M., Sharma, R., Russell, P., Kennedy, C., Fereday, S., Hung, J., Hogg, R., Wain, G., Brand, A., Balleine, R., Clarke, C., Harnett, P., deFazio, A., et al (2014). Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. *Clinical Cancer Research*, 20(24), 6618-6630. [More Information]

Au-Yeung, G., Webb, P., deFazio, A., Feredaye, S., Bressel, M., Mileschkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). *Gynecologic Oncology*, 133(1), 16-22. [More Information]

Charbonneau, B., Moysich, K., Kalli, K., Oberg, A., Vierkant, R., Fogarty, Z., Block, M., Maurer, M., Goergen, K., Fridley, B., deFazio, A., et al (2014). Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, 2(4), 332-340. [More Information]

Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Scientific Reports*, 4, 1-9. [More Information]

Beesley, V., Green, A., Wyld, D., O'Rourke, P., Wockner, L., deFazio, A., Butow, P., Price, M., Horwood, K., Clavarino, A., et al (2014). Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis. *Gynecologic Oncology*, 132(1), 130-136. [More Information]

Block, M., Charbonneau, B., Vierkant, R., Fogarty, Z., Bamlet, W., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2014). Variation in NF- κ B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, 23(7), 1421-1427. [More Information]

2013

Johnatty, S., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M., Henderson, M., Russell, A., Hedditch, E., Emmanuel, C., deFazio, A., et al (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. *Gynecologic Oncology*, 131(1), 8-14. [More Information]

White, K., Vierkant, R., Fogarty, Z., Charbonneau, B., Block, M., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. *Cancer Epidemiology Biomarkers and Prevention*, 22(5), 987-992. [More Information]

Baumbusch, L., Helland, A., Wang, Y., Liestl, K., Schaner, M., Holm, R., Etemadmoghadam, D., Alsop, K., Brown, P., Mitchell, G., deFazio, A., et al (2013). High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. *PloS One*, 8(1), 1-8. [More Information]

Sieh, W., Kobel, M., Longacre, T., Bowtell, D., deFazio, A., Goodman, M., Hogdall, E., Deen, S., Wentzensen, N., Moysich, K., et al (2013). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *The Lancet Oncology*, 14(9), 853-862. [More Information]

George, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., deFazio, A., Smyth, G., Levine, D., Mitchell, G., et al (2013). Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. *Clinical Cancer Research*, 19(13), 3474-3484. [More Information]

Jordan, S., Steer, C., deFazio, A., Quinn, M., Obermair, A.,

Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D., et al (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. *Gynecologic Oncology*, 129(2), 310-317. [More Information]

Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. *Gynecologic Oncology*, 130(1), 162-168. [More Information]

Verhaak, R., Tamayo, P., Yang, J., Hubbard, D., Zhang, H., Creighton, C., Fereday, S., Lawrence, M., Carter, S., Mermel, C., deFazio, A., et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *Journal of Clinical Investigation*, 123(1), 517-525. [More Information]

2012

Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M., Webb, P., Stewart, C., et al (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. *Journal of Clinical Oncology*, 30(21), 2654-2663. [More Information]

Lu, Y., Chen, X., Beesley, J., Johnatty, S., deFazio, A., Lambrechts, S., Lambrechts, D., Despiere, E., Vergotes, I., Chang-Claude, J., et al (2012). Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. *Twin Research and Human Genetics*, 15(5), 615-623. [More Information]

Cowin, P., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M., Harnett, P., deFazio, A., et al (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. *Cancer Research*, 72(16), 4060-4073. [More Information]

Wang, Z., Birkbak, N., Culhane, A., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K., Piao, H., deFazio, A., et al (2012). Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. *Clinical Cancer Research*, 18(20), 5806-5815. [More Information]

2011

Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. *PloS One*, 6(3), e17617-1-e17617-18. [More Information]

Hunter, S., Anglesio, M., Sharma, R., Gilks, B., Melnyk, N., Chiew, Y., deFazio, A., Longacre, T., Huntsman, D., Goringe, K., et al (2011). Copy Number Aberrations in Benign Serous

Ovarian Tumors: A Case for Reclassification? *Clinical Cancer Research*, 17(23), 7273-7282. [More Information]

Helland, A., Anglesio, M., George, J., Cowin, P., Johnstone, C., House, C., Sheppard, K., Etemadmoghadam, D., Melnyk, N., Rustgi, A., deFazio, A., et al (2011). Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. *PLoS One*, 6(4), 1-9. [More Information]

Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. *Clinical Cancer Research*, 17(8), 2538-2548. [More Information]

Huang, S., Johnatty, S., Gamazon, E., Kyung Im, H., Ziliak, D., Duan, S., Zhang, W., O' Kistner, E., Chen, P., Beesley, J., deFazio, A., et al (2011). Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. *Clinical Cancer Research*, 17(16), 5490-5500. [More Information]

Nagle, C., Francis, J., Nelson, A., Zorbas, H., Luxford, K., deFazio, A., Fereday, S., Bowtell, D., Green, A., Webb, P. (2011). Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. *Journal of Clinical Oncology*, 29(16), 2253-2258. [More Information]

McConechy, M., Anglesio, M., Kalloger, S., Yang, W., Senz, J., Chow, C., Heravi-Moussavi, A., Morin, G., deFazio, A., Mes-Masson, A., et al (2011). Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. *Journal of Pathology*, 223(5), 567-573. [More Information]

Pharoah, P., Palmieri, R., Ramus, S., Gayther, S., Andrulis, I., Anton-Culver, H., Antonenkova, N., Antoniou, A., Goldgar, D., deFazio, A., Gao, B., Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. *Clinical Cancer Research*, 17(11), 3742-3750. [More Information]

2010

Johal, H., Faedo, M., Faltas, J., Lau, A., Mousina, R., Cozzi, P., deFazio, A., Rawlinson, W. (2010). DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. *Journal of Medical Virology*, 82(6), 1044-1050. [More Information]

Ahmed Ashoure, A., Etemadmoghadam, D., Temple, J., Lynch, A., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *Journal of Pathology*, 221(1), 49-56. [More Information]

Johnatty, S., Beesley, J., Chen, X., MacGregor, S., Duffy, D., Spurdle, A., deFazio, A., Gava, N., Webb, P., Rossing, M., et al (2010). Evaluation of candidate stromal epithelial cross-talk

genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, 6(7), e1001016 - 1-e1001016 - 10. [More Information]

Hudson, T., Anderson, W., Aretz, A., Barker, A., Bell, C., Bernabe, R., Bhan, M., Calvo, F., Eerola, I., Gerhard, D., deFazio, A., Kench, J., et al (2010). International network of cancer genome projects. *Nature*, 464, 993-998. [More Information]

Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. *BMC Cancer*, 10(497), 1-11. [More Information]

Gordon, L., Scuffham, P., Beesley, V., Green, A., deFazio, A., Wyld, D., Clavarino, A., Australian Ovarian Cancer Study Group, (, Webb, P. (2010). Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. *International Journal of Gynecological Cancer*, 20(5), 757-765. [More Information]

Price, M., Butow, P., Costa, D., King, M., Aldridge, L., Fardell, J., deFazio, A., Webb, P. (2010). Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. *Medical Journal of Australia*, 193(5), S52-S57. [More Information]

2009

Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. *Clinical Cancer Research*, 15(4), 1417-1427. [More Information]

Shah, S., Kobel, M., Senz, J., Morin, R., Clarke, B., Wiegand, K., Leung, G., Zayed, A., deFazio, A., Bowtell, D. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. *New England Journal of Medicine*, 360(26), 2719-2729. [More Information]

Johnatty, S., Beesley, J., Chen, X., Spurdle, A., deFazio, A., Webb, P., Goode, E., Rider, D., Vierkant, R., Anderson, S. (2009). Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. *Twin Research and Human Genetics*, 12(3), 269-275. [More Information]

Price, M., Zachariae, R., Butow, P., deFazio, A., Patel (nee Chauhan), D., Espie, C., Friedlander, M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. *European Journal of Cancer*, 45(18), 3262-3270. [More Information]

2008

Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., AOCs, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. *Clinical Cancer Research*, 14(17), 5594-5601. [More Information]

Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. *Clinical Cancer Research*, 14(21), 6924-6932. [More Information]

Gava, N., Clarke, C., Bye, C., Byth Wilson, K., deFazio, A. (2008). Global gene expression profiles of ovarian surface epithelial cells in vivo. *Journal of Molecular Endocrinology*, 40, 281-296. [More Information]

Anglesio, M., Arnold, J., George, J., Tinker, A., Tohill, R., Waddell, N., Simms, L., Locandro, B., Fereday, S., Traficante, N., Russell, P., deFazio, A., et al (2008). Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. *Molecular Cancer Research*, 6(11), 1678-1690. [More Information]

Tohill, R., Tinker, A., George, J., Brown, R., Fox, S., Lade, S., Johnson, D., Trivett, M., Etemadmoghadam, D., Locandro, B., deFazio, A., et al (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. *Clinical Cancer Research*, 14(16), 5198-5208. [More Information]

O'Brien, P., Davies, M., Scurry, J., Smith, A., Barton, C., Henderson, M., Saunders, D., Gloss, B., Patterson, K., et al, Murali, R., Scolyer, R., Scurr, L., deFazio, A. (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. *British Journal of Cancer*, 98(6), 1085-1093. [More Information]

2007

Easton, D., Pooley, K., Dunning, A., Pharoah, P., Thompson, D., Ballinger, D., Struwing, J., Morrison, J., Field, H., Luben, R., Berry, G., Clarke, C., Eisenbruch, M., Maclurcan, M., Mann, G., Price, M., deFazio, A., et al (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*, 447(7148), 1087-1093. [More Information]

Krypuy, M., Ahmed Ashoure, A., Etemadmoghadam, D., Hyland, S., deFazio, A., Fox, S., Brenton, J., Bowtell, D., Dobrovic, A. (2007). High resolution melting for mutation scanning of TP53 exons 5-8. *BMC Cancer*, 7(open access), 1-13. [More Information]

Greenman, C., Vastrik, I., Cahill, D., Goldstraw, P., Brasseur, F., Looijenga, L., Weber, B., Chiew, Y., deFazio, A., Greaves, M., et al (2007). Patterns of somatic mutation in human cancer genomes. *Nature*, 446(7132), 153-158. [More

Information]

Catchpoole, D., deFazio, A., Devereaux, L., Hof, M., Schmidt, C., Thorne, H., Zeps, N., Fleming, M. (2007). The importance of biorepository networks: The Australasian Biospecimen Network-Oncology. *Australian Journal of Medical Science*, 28(1), 16-20.

2006

Arnett-Mansfield, R., Graham, J., Hanson, A., Mote, P., Gompel, A., Scurr, L., Gava, N., deFazio, A., Clarke, C. (2006). Focal subnuclear distribution of progesterone receptor is ligand-dependent and associated with transcriptional activity. *Molecular Endocrinology*, 21(1), 14-29. [More Information]

Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. *Gynecologic Oncology*, 100(2), 239-246. [More Information]

Mote, P., Arnett-Mansfield, R., Gava, N., deFazio, A., Mulac-Jericevic, B., Conneely, O., Clarke, C. (2006). Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. *Endocrinology*, 147(12), 5503-5512. [More Information]

2005

deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. *Patent No. 2005316200*.

Aghmesheh, M., Edwards, L., Clarke, C., Byth Wilson, K., Katzenellenbogen, B., Russell, P., Friedlander, M., Tucker, K., deFazio, A. (2005). Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. *Gynecologic Oncology*, 97(1), 16-25. [More Information]

Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. *International Journal of Cancer*, 117(6), 1049-54. [More Information]

2004

Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. *International Journal of Gynecological Pathology*, 23(2), 138-144. [More Information]

Gava, N., Clarke, C., Byth Wilson, K., Arnett-Mansfield, R., deFazio, A. (2004). Expression Of Progesterone Receptors A And B In The Mouse Ovary During The Estrous Cycle. *Endocrinology*, 145(7), 3487-3494. [More Information]

Arnett-Mansfield, R., deFazio, A., Mote, P., Clarke, C. (2004). Subnuclear Distribution Of Progesterone Receptors A And B In Normal And Malignant Endometrium. *The Journal of Clinical*

Endocrinology and Metabolism, 89(3), 1429-1442. [More Information]

2002

Kennedy, C., Byth, K., Clarke, C., deFazio, A. (2002). Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate. *Molecular Cancer Therapeutics*, 1(12), 1025-1033.

Guminski, A., Harnett, P., deFazio, A. (2002). Scientists and clinicians test their metal - back to the future with platinum compounds. *The Lancet Oncology*, 3(5), 312-318. [More Information]

2001

Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. *Cancer Chemotherapy and Pharmacology*, 48(3), 229-234.

Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. *Today's Life Science (Australia)*, 13(2), 36-40.

Arnett-Mansfield, R., Wain, G., Jaworski, R., Mote, P., Clarke, C., deFazio, A., Byth, K. (2001). Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium1. *Cancer Research*, 61, 4576-4582.

2000

deFazio, A., Chiew, Y., Sini, R., Janes, P., Sutherland, R. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. *International Journal of Cancer*, 87(4), 487-498.

Davis, T., Kennedy, C., Chiew, Y., Clarke, C., deFazio, A. (2000). Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. *Clinical Cancer Research*, 6(11), 4334-4342.